Teva Pharmaceutical Industries Ltd., will send out chief financial officer Eyal Desheh to juggle, er, talk to analysts Tuesday when he and they gather at the Goldman Sachs 35th Annual Global Healthcare Conference in Rancho Palos Verdes, Calif. Desheh might as well be juggling because Teva has a lot of balls in the air. Last week, Teva said it would acquire privately held Labrys Biologics, Inc. for $200 million up front and as much as $625 million more if Labrys’ key drug for migraine pain pans out.
Help employers find you! Check out all the jobs and post your resume.
